Table 2 Median relative dose intensities and duration of exposure in the Asian and non-Asian subsets (safety set)
|  | Overall population | HR– subpopulation | ||||||
|---|---|---|---|---|---|---|---|---|
Asian | Non-Asian | Asian | Non-Asian | |||||
EVE + TRAS + PAC | PBO + TRAS + PAC | EVE + TRAS + PAC | PBO + TRAS + PAC | EVE + TRAS + PAC | PBO + TRAS + PAC | EVE + TRAS + PAC | PBO + TRAS + PAC | |
n = 196 | n = 104 | n = 276 | n = 134 | n = 85 | n = 47 | n = 121 | n = 56 | |
Relative dose intensity, median (range) | ||||||||
 EVE | 0.51 (0.03–1.00) | 0.95 (0.01–1.00) (PBO) | 0.57 (0.05–1.00) | 0.97 (0.12–1.00) (PBO) | 0.50 (0.03–1.00) | 0.95 (0.13–1.00) (PBO) | 0.61 (0.05–1.00) | 0.96 (0.29–1.00) (PBO) |
 TRAS | 0.96 (0.28–1.08) | 0.97 (0.75–1.03) | 0.96 (0.08–1.16) | 0.96 (0.41–1.06) | 0.98 (0.49–1.08) | 0.97 (0.78–1.02) | 0.97 (0.37–1.12) | 0.96 (0.61–1.03) |
 PAC | 0.65 (0.01–1.09) | 0.72 (0.08–1.22) | 0.72 (0.04–1.40) | 0.84 (0.11–1.25) | 0.65 (0.01–1.08) | 0.82 (0.08–1.22) | 0.73 (0.11–1.40) | 0.79 (0.13–1.00) |
Duration of exposure, median (range), weeks | ||||||||
 EVE | 42.14 (0.6–241.7) | 59.93 (2.0–240.7) | 40.00 (1.1–233.1) | 40.71 (1.1–207.4) | 45.86 (0.6–210.4) | 41.29 (2.1–221.1) | 44.71 (1.4–233.1) | 38.50 (1.1–207.4) |
 TRAS | 58.07 (3.0–242.3) | 64.07 (3.0–241.0) | 45.00 (1.0–233.7) | 40.43 (1.0–208.0) | 58.29 (3.0–211.0) | 41.00 (3.0–221.9) | 49.86 (2.0–233.7) | 38.50 (4.0–208.0) |
 PAC | 36.50 (1.0–201.0) | 37.14 (1.0–230.0) | 27.07 (1.0–155.1) | 30.00 (1.0–174.0) | 35.00 (1.0–201.0) | 35.00 (1.0–190.0) | 28.86 (2.0–141.7) | 27.00 (1.0–167.9) |